Status:
COMPLETED
Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborating Sponsors:
St George's, University of London
Mologic Ltd
Conditions:
Infectious Disease
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
People with cancer may be at higher risk of poor outcomes with COVID-19 infection. This observational study aims to describe the clinical course of COVID-19 infection in people with cancer and evaluat...
Detailed Description
Patients with cancer are thought to have a weakened immune system and small observational case series have suggested patients with cancer are at a higher risk of poor outcome from COVID-19. However, t...
Eligibility Criteria
Inclusion
- Suspected COVID-19 infection undergoing diagnostic testing by SARS-CoV-2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
- Metastatic or advanced solid organ malignancy, including lymphoma OR Early stage solid organ malignancy having received therapy (radiotherapy, chemotherapy or targeted agents)
- Patient is ≥ 18 years of age.
- Patient can understand the patient information sheet and is able to provide written informed consent.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
May 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 29 2021
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT04427280
Start Date
May 26 2020
End Date
June 29 2021
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Marden NHS Foundation Trust
Sutton, Surrey, United Kingdom, SM2 5PT